Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocodex Develops DIACOMIT® Oral Suspension for Dravet Syndrome in Children
Details : Diacomit (stiripentol) a GABA-A receptor inhibitor oral suspension, a new formulation is being investigated to aid in the treatment of dravet syndrome in young children.
Product Name : Diacomit
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2024
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stiripentol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Exystat
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2024
Lead Product(s) : Stiripentol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Exystat
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amoxicillin Trihydrate
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 11, 2024
Lead Product(s) : Amoxicillin Trihydrate
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stiripentol
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2023
Lead Product(s) : Stiripentol
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Recipient : Hilma
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The acquisition is a key part of the Group’s international growth strategy and will enable Biocodex to consolidate its presence in the digestive health and women’s health segments of the US market.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 17, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : Hilma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antiseizure Drug DIACOMIT Now Approved for Children as Young as 6 Months
Details : DIACOMIT (stiripentol) is an effective treatment for seizures that are often resistant to other antiepileptic drugs. In two clinical studies, DIACOMIT reduced generalized clonic or tonic-clonic seizures by a median of 84% compared with 5.8% on placebo af...
Product Name : Diacomit
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : PANTHERx Rare Pharmacy
Deal Size : Undisclosed
Deal Type : Partnership
Details : DIACOMIT (stiripentol), is a molecular entity approved by the FDA for the adjunctive treatment of seizures associated with Dravet syndrome in 2 years of age and older taking clobazam. An orally administered, DIACOMIT is given as either a capsule or powde...
Product Name : Diacomit
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 27, 2022
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : PANTHERx Rare Pharmacy
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2022
Lead Product(s) : Stiripentol
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stiripentol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2019
Lead Product(s) : Stiripentol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Stiripentol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Diacomit
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2019
Lead Product(s) : Stiripentol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable